National Institute of Allergy and Infectious Diseases
  National Institutes of Health
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Research
 Research by Topic
 Research Resources


HIV/AIDS
 Basic Science
 Epidemiology
 Prevention
 Therapeutics
 Vaccines
  Introduction and Goals
  Research Activities
  Advisory and Working Groups
  Resources for Researchers
   Guidelines for Requesting Access to Animal Models and Vaccine Reagents
   Simian Vaccine Evaluation Units (SVEU)
   Vaccine Reagent Resource
   Preclinical Master Contract
  Funding
  Meetings
  Reports and Articles
  Clinical Trials

HIV/AIDS

Vaccines

Simian Vaccine Evaluation Units (SVEU)

The SVEU contracts serve as a resource to evaluate promising SIV and HIV vaccines in nonhuman primates in support of HIV vaccine development.

Proposals from investigators for vaccine studies (see guidelines for submission of proposals) are evaluated by NIAID, and approved studies are conducted at one of the three SVEU contract sites.  Studies conducted at the SVEUs are collaborative with the vaccine investigator working with the SVEU Principal Investigator and the SVEU Project Officer on study design and data evaluation.

The SVEU provides the nonhuman primates for studies to evaluate candidate SIV or HIV vaccines.  The SVEU contractor will immunize nonhuman primates with the candidate vaccine, and together with the Primate Immunology Laboratory, can evaluate humoral and cellular immune responses.  The SVEU can also challenge the animals with SIV or SHIV virus, can determine the levels of replicating virus post-challenge, and will evaluate disease outcomes.

The SVEUs conduct several types of studies:

  • Preliminary studies on new vaccines
  • Efficacy studies with vaccines that have already demonstrated promise 
  • Studies with passively administered products
  • In vivo titration of virus challenge stocks
  • Evaluation of the immunogenicity and safety of candidate HIV vaccines or SIV vaccines (that parallel HIV vaccines in approach) in support of Phase I human clinical trials
  • Comparative studies on vaccines and/or adjuvants from multiple sources

Current SVEU Contractors

Advanced BioScience Laboratories
Kensington, MD
Dr. Phillip Markham

Bioqual
Rockville, MD
P.I.: Dr. Mark Lewis

University of Washington
Seattle, WA
Dr. David Anderson

Current Primate Immunology Laboratory Contractors

Cellular Immune Assays
Beth Israel Hospital
Boston, MA
Dr. Norman Letvin

Virus Neutralization Assays
Duke University
Durham, NC
Dr. David Montefiori

Current Virology Laboratory Contractor

Advanced BioSciences Laboratories
Kensington, MD
Dr. Ranajit Pal

For additional Information and to request SVEU study application forms, contact:

Dr. Nancy Miller
Division of AIDS, Preclinical Research and Development Branch
Phone: 310-435-3753
E-mail: nmiller@niaid.nih.gov

Dr. Jon Warren
Division of AIDS, Preclinical Research and Development Branch
Phone: 301-402-0633
E-mail: jwarren@niaid.nih.gov

Dr. Yen Li
Division of AIDS, Preclinical Research and Development Branch
Phone: 301-496-3816
E-mail: yli@niaid.nih.gov

back to top


See Also

Division of AIDS

HIV/AIDS Vaccines

HIV/AIDS Publications

HIV/AIDS News Releases

Global Research, Africa

Highlights

25 Years of HIV/AIDS Science: Reaching the Poor with Research Advances (Commentary by NIAID Director Anthony S. Fauci published in Cell)—Nov. 2, 2007
Search in Research
 
E-mail Icon E-mail this page
Print Icon Print this page
Plug-ins and Viewers
To open PDFs on this page, download and install the Adobe Acrobat Reader.
To play audio/video content on this page, visit the plug-in page.

See Also

Division of AIDS

HIV/AIDS Vaccines

HIV/AIDS Publications

HIV/AIDS News Releases

Global Research, Africa

Highlights

25 Years of HIV/AIDS Science: Reaching the Poor with Research Advances (Commentary by NIAID Director Anthony S. Fauci published in Cell)—Nov. 2, 2007